WXXWY News and Press, Wuxi Biologics Cayman Inc ADR From 11/09/20

AC Immune (ACIU) and WuXi Biologics (WXXWY) plan to accelerate advancement of AC Immune’s TDP-43 antibody into clinical development for NeuroOrphan indications. This next phase of the strategic partnership between the companies builds on the know-how of ACIU's drug discovery and develo...

Antengene Announces Collaboration with WuXi Biologics to Advance the Development of Innovative Oncology Medicines PR Newswire SHANGHAI, Oct. 10, 2020 SHANGHAI , Oct. 10, 2020 /PRNewswire/ -- Antengene Corporation, a leading innovative biopharmaceutical c...

Shrugging off COVID-19-related disruptions, WuXi Biologics ( OTCPK:WXXWY ) delivered a 21.0% increase in H1 revenue (RMB1,944.1M). Gross profit surged 17.3% to RMB787.3M. More news on: Wuxi Biologics (Cayman) Inc ADR, WuXi Biologics (Cayman) Inc., Healthcare stocks news, Earnings news an...

Revenue Up 21.0% Y-o-Y to RMB1,944.1 Million Net Profit Up 62.6% to RMB730.7 Million Profit Attributable to Owners of the Company Up 63.6% Y-o-Y to RMB736.1 Million Adjusted Net Profit Up 40.7% Y-o-Y to RMB734.0 Million Diluted EPS Up 55.9% Y-o-Y to RMB0.53 Adjusted Dilu...

Wuxi Biologics ADR ( OTCPK:WXXWY ) : H1 Non-GAAP EPS of RMB0.54; GAAP EPS of RMB0.53. Revenue of RMB1.94B (+21.0% Y/Y). Total backlog grew from $5.1B as of Dec. 31, 2019 to ~$9.46B as of June 30, 2020. Press Release More news on: Wuxi Biologics (Cayman) Inc ADR, WuXi Biologics (Ca...

WuXi Vaccines, a joint venture between WuXi Biologics ( OTCPK:WXXWY ) and Shanghai-based Hile Bio-Technology has appointed Mr. Jian Dong as Chief Executive Officer. More news on: Wuxi Biologics (Cayman) Inc ADR, WuXi Biologics (Cayman) Inc., Healthcare stocks news, Rea...

SHANGHAI and DUNDALK, Ireland , Aug. 6, 2020 /PRNewswire/ -- WuXi Vaccines, a global leading company with world-class vaccine contract development and manufacturing organization (CDMO) capabilities, is pleased to announce the appointment of Mr. Jian Dong as Chief Executive Office...

SHANGHAI , Aug. 4, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that it was awarded as "Most Honored Company" by Institutional Investor , an international financial publication, based on th...

SHANGHAI , June 19, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that its 2 nd Investor Day with the theme of "Embrace Change to Turn Challenges into Opportunities", was successfully held o...

One of few third-party biosafety testing providers certified by EMA GMP standards in China even Asia-Pacific region SUZHOU, China , June 16, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, a...